This is a StreetInsider.com Premium Only Page

(ANAB) – StreetInsider.com Reports

Apr 16, 2024 07:27 AM Leerink Partners Starts AnaptysBio (ANAB) at Outperform

Apr 11, 2024 05:20 AM Wells Fargo Starts AnaptysBio (ANAB) at Overweight

Apr 1, 2024 10:06 AM AnaptysBio (ANAB) PT Lowered to $28 at JPMorgan

Mar 12, 2024 06:04 AM Wedbush Upgrades AnaptysBio (ANAB) to Outperform

Mar 11, 2024 04:58 PM AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 4c

Feb 26, 2024 06:28 AM BTIG Starts AnaptysBio (ANAB) at Buy, 'Novel Therapies in Large Markets Make a Compelling Case for Upside'

Feb 21, 2024 08:04 AM Anaptysbio (ANAB) a key player in next wave of immune cell modulatory therapies - Stifel

Feb 20, 2024 04:09 PM Stifel Starts AnaptysBio (ANAB) at Buy

Feb 16, 2024 12:00 PM Piper Sandler sees a potential 250% upside in this biotech stock

Feb 16, 2024 04:46 AM Piper Sandler Starts AnaptysBio (ANAB) at Overweight

Nov 27, 2023 04:16 PM Anaptysbio (ANAB) Enters Exclusive License for BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (CNTA)

Nov 3, 2023 05:17 AM AnaptysBio (ANAB) PT Lowered to $44 at Guggenheim

Nov 1, 2023 08:16 AM AnaptysBio (ANAB) PT Lowered to $21 at UBS

Oct 26, 2023 12:07 PM AnaptysBio (ANAB) PT Lowered to $18 at Wedbush

Oct 9, 2023 08:02 AM Anaptysbio (ANAB) Phase 3 Clinical Trial of Imsidolimab Met its Primary Endpoint

Oct 9, 2023 07:55 AM Anaptysbio (ANAB) Halted, News Pending

Sep 18, 2023 04:15 PM Anaptysbio (ANAB) Announces Appointment of John Orwin as Chairman of the Board of Directors

Aug 9, 2023 12:46 PM AnaptysBio (ANAB) PT Lowered to $20 at Truist Securities

Aug 8, 2023 07:21 AM AnaptysBio (ANAB) PT Lowered to $26 at Wedbush

Aug 7, 2023 05:15 PM AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 20c

Jul 31, 2023 01:36 PM Anaptysbio (ANAB) and GSK’s JEMPERLI plus Chemo Approved in the US for dMMR/MSI-H Cancer

May 22, 2023 03:58 AM JPMorgan Upgrades AnaptysBio (ANAB) to Neutral

May 2, 2023 09:16 AM Anaptysbio (ANAB) Announces Publication of Imsidolimab Previously Reported Phase 2 GALLOP Data

Apr 12, 2023 06:51 AM AnaptysBio (ANAB) PT Lowered to $31 at JPMorgan

Apr 6, 2023 04:16 PM Anaptysbio (ANAB) Appoints Rita Jain to its Board

Mar 28, 2023 05:49 AM GSK (GSK) and AnaptysBio (ANAB) Report Jemperli plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-free Survival

Feb 8, 2023 02:41 AM AnaptysBio (ANAB) PT Raised to $30 at Jefferies

Jan 13, 2023 09:00 AM Anaptysbio (ANAB) Announces Stock Repurchase Plan

Jan 6, 2023 06:27 AM Raymond James Downgrades AnaptysBio (ANAB) to Market Perform

Jan 6, 2023 06:20 AM AnaptysBio (ANAB) PT Lowered to $29 at Wedbush

Jan 5, 2023 04:08 PM Anaptysbio (ANAB) Announces Portfolio Update

Dec 2, 2022 09:01 AM Anaptysbio (ANAB), GSK (GSK) -partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

Nov 18, 2022 06:56 AM AnaptysBio (ANAB) PT Raised to $32 at JPMorgan

Nov 9, 2022 07:14 AM AnaptysBio (ANAB) PT Raised to $38 at Raymond James

Nov 1, 2022 06:29 AM UPDATE: Guggenheim Upgrades AnaptysBio (ANAB) to Buy

Oct 5, 2022 09:01 AM Anaptysbio (ANAB), GSK (GSK) -partnered immuno-oncology agents JEMPERLI and cobolimab show positive progress in two separate NSCLC trials

Sep 19, 2022 06:43 AM UPDATE: H.C. Wainwright Assumes AnaptysBio (ANAB) at Buy

Sep 13, 2022 07:34 AM UPDATE: Truist Securities Downgrades AnaptysBio (ANAB) to Hold

Sep 12, 2022 07:31 AM Anaptysbio (ANAB) Announces Sale of Zejula Royalties for Up To $45 Million

Sep 1, 2022 09:15 AM Pre-Open Movers: Okta Sinks on Disappointing Results, Nutanix Gains on Solid Beat

Aug 31, 2022 05:17 PM After-Hours Stock Movers: Nutanix Jumps on Beat, C3.ai Falls on Revenue Miss

Aug 31, 2022 04:23 PM UPDATE: Raymond James Starts AnaptysBio (ANAB) at Outperform

Aug 31, 2022 04:16 PM Anaptysbio (ANAB) Reports HARP Phase 2 Top-Line Data of Imsidolimab

Apr 27, 2022 04:16 PM Anaptysbio (ANAB) Reports Positive ANB032 Top-Line Phase 1 Data; Provides Pipeline Updates

Mar 22, 2022 06:57 AM Guggenheim Downgrades AnaptysBio (ANAB) to Neutral

Mar 21, 2022 04:16 PM Anaptysbio (ANAB) Appoints Daniel Faga As Interim CEO

Mar 18, 2022 09:03 AM AnaptysBio (ANAB) PT Lowered to $24 at JPMorgan

Mar 15, 2022 09:31 AM Pre-Open Stock Movers 03/15: (HYMC) (GTLB) (HOLI) Higher; (COUP) (ANAB) (CTRN) Lower (more...)

Mar 14, 2022 05:55 PM After-Hours Stock Movers 03/14: (GTLB) (WPRT) (TLYS) Higher; (COUP) (ANAB) (EXEL) Lower (more...)

Mar 14, 2022 04:27 PM Anaptysbio (ANAB) to Resume Trading at 4:50 p.m.